Pluri Inc.
PLUR
Rank in Stocks
#27293
Based in Haifa, Israel, and established in 2001, Pluri Inc. is a biotechnology... Based in Haifa, Israel, and established in 2001, Pluri Inc. is a biotechnology company dedicated to advancing placenta-derived cell therapies. Its primary goal is to address a spectrum of health issues, including inflammatory conditions, muscle damage, and blood disorders. The company's core development involves placental expanded (PLX) cell products. A leading candidate, PLX-PAD, is currently in a Phase III clinical trial to improve muscle recovery following hip fracture surgery. It is also undergoing a Phase I/II trial, in partnership with Tel Aviv Sourasky Medical Center, for the treatment of steroid-refractory graft versus host disease. Furthermore, PLX-PAD has successfully completed a Phase II clinical trial for acute respiratory distress syndrome linked to COVID-19 and a Phase I trial for patients with incomplete recovery after bone marrow transplantation. Another key product, PLX-R18, is being developed to aid in the recovery of blood cell production following hematopoietic cell transplantation. Pluri is also collaborating with the National Institutes of Health and the U.S. Department of Defense to create a therapeutic solution for acute radiation syndrome. The company, formerly known as Pluristem Therapeutics Inc., adopted its current name, Pluri Inc., in July 2022.
Share Price
$1.18
Last synced: 2026-11-09
Market Cap
$15.80M
Change (1 day)
-4.48%
Change (1 year)
-71.50%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Pluri Inc. (PLUR)
Category
Healthcare
EPS for Pluri Inc. (PLUR)
EPS as of June 2026 TTM: $-2.45
According to Pluri Inc.'s latest financial reports, its current EPS (TTM) is $-2.45. At the end of 2025 the company had an EPS of $-3.56, an increase over its 2024 EPS of $-3.99.
EPS history for Pluri Inc. from 2002 to 2026
EPS at the end of each year
| Year | EPS | Change |
|---|---|---|
| 2026 (TTM) | $-2.45 | -31.18% |
| 2025 | $-3.56 | -10.78% |
| 2024 | $-3.99 | -35.44% |
| 2023 | $-6.18 | -39.65% |
| 2022 | $-10.24 | -27.84% |
| 2021 | $-14.19 | 10.86% |
| 2020 | $-12.80 | -44.83% |
| 2019 | $-23.20 | 17.53% |
| 2018 | $-19.74 | -22.44% |
| 2017 | $-25.45 | 8.85% |
| 2016 | $-23.38 | -16.77% |
| 2015 | $-28.09 | -17.19% |
| 2014 | $-33.92 | 11.21% |
| 2013 | $-30.50 | 13.47% |
| 2012 | $-26.88 | -3.38% |
| 2011 | $-27.82 | -20.65% |
| 2010 | $-35.06 | -29.98% |
| 2009 | $-50.07 | -61.71% |
| 2008 | $-130.77 | -72.03% |
| 2007 | $-467.52 | -26.95% |
| 2006 | $-639.99 | 215.48% |
| 2005 | $-202.86 | 68.57% |
| 2004 | $-120.34 | 334.28% |
| 2003 | $-27.71 | 494.64% |
| 2002 | $-4.66 | 0.00% |
EPS for similar companies or competitors
| Company | EPS | EPS Difference | Country |
|---|---|---|---|
| $15.66 | -739.18% |
US
|
|
| $-7.07 | 188.57% |
US
|
|
| $-5.29 | 115.92% |
AU
|
|
| $12.88 | -625.72% |
BE
|
|
| $21.56 | -980.00% |
NL
|
Questions about Pluri Inc.'s earnings per share (EPS)
What is Pluri Inc.'s earnings per share (EPS)?
Pluri Inc.'s earnings per share (EPS) over the last twelve months is $-2.45, as of Jun 2026.
What was Pluri Inc.'s earnings per share (EPS) in 2025?
In 2025, Pluri Inc.'s earnings per share (EPS) was $-3.56, compared with $-3.99 in 2024.
How has Pluri Inc.'s earnings per share (EPS) changed since 2020?
From 2020 to 2025, Pluri Inc.'s earnings per share (EPS) was highest in 2025 ($-3.56) and lowest in 2021 ($-14.19).
How does Pluri Inc.'s earnings per share (EPS) compare with similar companies?
Pluri Inc.'s earnings per share (EPS) ($-2.45) is higher than that of 2 of the 5 similar companies listed above. The highest among them is Argenx SE, with $21.56.